The ICSC project
The ICSC – a research for SME project - was finalized September 1st 2011 after a project period of 2½ years.
The project constituted highly cross disciplinary research and development performed by world class scientist groups and SMEs from 4 different EU- or EU associated countries. The partners were:
The ICSC project has successfully developed a technology that uniquely is capable of identifying novel drug candidates showing efficacy in cancer cells from tumour tissue isolated from individual colorectal cancer patients. Very importantly the ICSC project was developed in direct interaction with the end-users being hospitals and academic institutions. This has led to an exciting expansion of the ICSC technology to go from cell functional testing of individual compounds to testing of compounds in combination of already registered drugs that are used in the adjuvant treatment of colorectal cancer patients. The technology will in its finally developed form be applicable for optimization of the chemotherapeutic treatment of patients by identifying the combination of drugs that shows efficacy and lack of resistance in the individual patient.
The ICSC project has had immediate impact and is expected to have a major impact longer term. Immediate impact:
Longer-term impact:
The project constituted highly cross disciplinary research and development performed by world class scientist groups and SMEs from 4 different EU- or EU associated countries. The partners were:
2cureX A/S (coordinator); SME – Denmark
Microliquid; SME – Spain
Protein laboratories Rehovot; SME – Israel
University Southampton; RTD – UK
Danish technical University (DTU); RTD –Denmark
Bispebjerg Hospital (BBH); RTD - Denmark
Microliquid; SME – Spain
Protein laboratories Rehovot; SME – Israel
University Southampton; RTD – UK
Danish technical University (DTU); RTD –Denmark
Bispebjerg Hospital (BBH); RTD - Denmark
SME: Small and Medium-sized Enterprises; RTD: Research and Technology Development providers.
The objective of the ICSC project was to develop
- A comprehensive technology that opens for screening of large chemical libraries against primary cells from cancer patients.
- Furthermore a technology was developed that allows screening of combination libraries against primary cancer cells from a patient’s tumour for the purpose of identifying the most efficacious treatment for the individual patient.
Final results and associated impact
The ICSC project has successfully developed a technology that uniquely is capable of identifying novel drug candidates showing efficacy in cancer cells from tumour tissue isolated from individual colorectal cancer patients. Very importantly the ICSC project was developed in direct interaction with the end-users being hospitals and academic institutions. This has led to an exciting expansion of the ICSC technology to go from cell functional testing of individual compounds to testing of compounds in combination of already registered drugs that are used in the adjuvant treatment of colorectal cancer patients. The technology will in its finally developed form be applicable for optimization of the chemotherapeutic treatment of patients by identifying the combination of drugs that shows efficacy and lack of resistance in the individual patient.
The ICSC project has had immediate impact and is expected to have a major impact longer term. Immediate impact:
- A comprehensive technology has been developed that opens for screening of large chemical libraries against primary cells from cancer patients.
- An easy-to-use technology has been developed that allows screening of combination libraries against primary cancer cells from individual patients.
- Two papers accepted in international, peer reviewed journals.
- Use of the technology at hospitals to design the combination therapy that is matched to the individual colorectal cancer patient. Such technology will both improve treatment quality and raise the cost efficiency providing a positive impact on the health care systems.
- Further we see a huge potential in identifying novel drug candidates that in combination with established cancer treatment regimens will improve patient outcome.
- Roll-out of the technology to other cancer types than colorectal cancer.
ICSC contact
| Coordinator: | Ole Thastrup, 2cureX |
| Tel: +45 2211 5399 e-mail: ot@2curex.com URL: www.icsc-fp7.eu |